X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (884) 884
Publication (82) 82
Book Review (9) 9
Conference Proceeding (3) 3
Book / eBook (2) 2
Book Chapter (2) 2
Magazine Article (2) 2
Data Set (1) 1
Reference (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (837) 837
hiv infections - drug therapy (578) 578
dideoxynucleosides - adverse effects (568) 568
male (432) 432
anti-hiv agents - adverse effects (416) 416
female (392) 392
dideoxynucleosides - therapeutic use (387) 387
adult (355) 355
index medicus (354) 354
infectious diseases (302) 302
anti-hiv agents - therapeutic use (281) 281
middle aged (276) 276
abacavir (272) 272
hiv (222) 222
dideoxynucleosides - administration & dosage (212) 212
reverse transcriptase inhibitors - adverse effects (211) 211
immunology (190) 190
pharmacology & pharmacy (185) 185
drug therapy, combination (172) 172
lamivudine - therapeutic use (157) 157
reverse transcriptase inhibitors - therapeutic use (154) 154
anti-hiv agents - administration & dosage (146) 146
antiretroviral therapy (135) 135
drug combinations (134) 134
lamivudine - adverse effects (126) 126
lamivudine - administration & dosage (119) 119
hla-b antigens - genetics (118) 118
tenofovir (116) 116
virology (116) 116
treatment outcome (115) 115
lamivudine (113) 113
cd4 lymphocyte count (111) 111
drug hypersensitivity - genetics (111) 111
viral load (104) 104
antiviral agents (103) 103
adenine - analogs & derivatives (101) 101
hiv-1 (101) 101
hiv infections - virology (100) 100
hiv infection (97) 97
drug therapy (96) 96
hiv infections - complications (91) 91
zidovudine (89) 89
aged (88) 88
therapy (88) 88
risk factors (87) 87
aids (85) 85
zidovudine - therapeutic use (84) 84
pharmacogenetics (82) 82
microbiology (80) 80
hiv infections - immunology (77) 77
antiretroviral therapy, highly active - adverse effects (75) 75
zidovudine - adverse effects (74) 74
drug hypersensitivity - etiology (73) 73
hiv-1 - drug effects (71) 71
reverse transcriptase inhibitors - administration & dosage (70) 70
dideoxynucleosides - pharmacology (68) 68
human immunodeficiency virus--hiv (68) 68
adenine - therapeutic use (65) 65
antiretroviral therapy, highly active (65) 65
reverse-transcriptase inhibitors (65) 65
adolescent (64) 64
medicine, general & internal (64) 64
hypersensitivity (63) 63
hiv-infected patients (62) 62
zidovudine - administration & dosage (62) 62
drug hypersensitivity (61) 61
aids/hiv (60) 60
antiretroviral drugs (60) 60
emtricitabine (60) 60
research (60) 60
efavirenz (59) 59
animals (57) 57
health aspects (57) 57
safety (57) 57
myocardial-infarction (56) 56
protease inhibitors (56) 56
benzoxazines (54) 54
drug administration schedule (54) 54
adenine - adverse effects (53) 53
association (53) 53
dideoxynucleosides (52) 52
hiv protease inhibitors - therapeutic use (52) 52
rna, viral - blood (52) 52
clinical trials as topic (51) 51
drug hypersensitivity - immunology (51) 51
prospective studies (51) 51
dideoxynucleosides - pharmacokinetics (50) 50
highly active antiretroviral therapy (50) 50
hla-b-asterisk-5701 (50) 50
organophosphonates - therapeutic use (50) 50
retrospective studies (50) 50
risk (50) 50
deoxycytidine - analogs & derivatives (49) 49
human immunodeficiency virus (49) 49
care and treatment (48) 48
drugs (47) 47
clinical trials (46) 46
young adult (46) 46
antiretroviral therapy, highly active - methods (45) 45
genotype (45) 45
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (842) 842
German (18) 18
Spanish (11) 11
French (8) 8
Italian (3) 3
Chinese (2) 2
Russian (2) 2
Japanese (1) 1
Swedish (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 6/2011, Volume 203, Issue 12, pp. 1791 - 1801
Background. Long-term effects of abacavir (ABC)-lamivudine (3TC), compared with tenofovir (TDF)-emtricitabine (FTC) with efavirenz (EFV) or atazanavir plus... 
HIV/AIDS | Percentage change | RNA | Spine | Bones | Bone density | Arm | Hip | Bone fractures | HIV 1 | Arts | INFECTIOUS DISEASES | EFFICACY | INITIATION | MICROBIOLOGY | PREVALENCE | IMMUNOLOGY | COMBINATION | OSTEOPOROSIS | HIV-INFECTED PATIENTS | WOMEN | THERAPY | COHORT | HEALTH | Humans | Middle Aged | Antiretroviral Therapy, Highly Active - adverse effects | Fractures, Bone - epidemiology | Male | Oligopeptides - adverse effects | Viral Load | Lamivudine - adverse effects | Tenofovir | Pyridines - adverse effects | Adenine - adverse effects | Ritonavir - adverse effects | Atazanavir Sulfate | Adult | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Drug Therapy, Combination | Emtricitabine | Adenine - analogs & derivatives | Osteoporosis - chemically induced | Anti-HIV Agents - adverse effects | Risk Factors | Organophosphonates - adverse effects | Benzoxazines - adverse effects | CD4 Lymphocyte Count | Absorptiometry, Photon | Bone Density - drug effects | HIV Infections - complications | Intention to Treat Analysis | HIV Infections - drug therapy | Fractures, Bone - chemically induced | Deoxycytidine - analogs & derivatives | Drug Combinations | Usage | Care and treatment | Ritonavir | Drug utilization | Lamivudine | Efavirenz | Prevention | Abacavir | Dosage and administration | Drug therapy, Combination | Drug therapy | HIV infection | Major and Brief Reports
Journal Article
AIDS, ISSN 0269-9370, 07/2009, Volume 23, Issue 12, pp. 1547 - 1556
Background: Abacavir sulfate/lamivudine (ABC/3TC) and tenofovir DF/emtricitabine (TDF/FTC) are widely used nucleoside reverse transcriptase inhibitors for... 
Emtricitabine | Tenofovir | Ritonavir | Lopinavir | Abacavir | Lamivudine | Antiretroviral therapy | emtricitabine | INFECTIOUS DISEASES | MYOCARDIAL-INFARCTION | tenofovir | antiretroviral therapy | NAIVE HIV-1-INFECTED PATIENTS | IMMUNOLOGY | REVERSE-TRANSCRIPTASE INHIBITORS | VIROLOGY | lopinavir | ritonavir | RENAL-FAILURE | abacavir | SOCIETY-USA PANEL | INFECTED PATIENTS | 2008 RECOMMENDATIONS | FANCONI-SYNDROME | lamivudine | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Male | RNA, Viral - blood | Lamivudine - adverse effects | HIV Infections - immunology | Deoxycytidine - therapeutic use | Adenine - adverse effects | Ritonavir - adverse effects | Adenine - therapeutic use | HIV-1 - isolation & purification | Lamivudine - therapeutic use | Ritonavir - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Dideoxynucleosides - therapeutic use | Antiretroviral Therapy, Highly Active - methods | Adenine - analogs & derivatives | Double-Blind Method | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | HIV Infections - virology | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Organophosphonates - adverse effects | Treatment Outcome | CD4 Lymphocyte Count | HIV-1 - genetics | HIV Infections - drug therapy | Cardiovascular Diseases - chemically induced | Deoxycytidine - analogs & derivatives | Index Medicus | AIDS/HIV
Journal Article
The Journal of Infectious Diseases, ISSN 0022-1899, 4/2013, Volume 207, Issue 7, pp. 1157 - 1165
Background. Human immunodeficiency virus (HIV)-infected patients on combination active antiretroviral therapy (cART) are at increased risk of age-related... 
T lymphocytes | HIV/AIDS | Telomeres | Antiretrovirals | HIV | Final causes | Cell lines | Nucleosides | Reverse transcriptase inhibitors | Carts | Disease risks | telomerase | aging | HIV infection | antiretroviral therapy | telomere | INFECTIOUS DISEASES | HUMAN HL60 CELLS | ANTIRETROVIRAL NUCLEOSIDE | ALZHEIMERS-DISEASE | LENGTH | MICROBIOLOGY | IMMUNOLOGY | CANCER | CD8(+) T-CELLS | IN-VITRO | THERAPY | INFECTION | UP-REGULATION | Humans | Middle Aged | Aging - drug effects | Antiretroviral Therapy, Highly Active - adverse effects | Male | Telomere - drug effects | Case-Control Studies | Lamivudine - adverse effects | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Young Adult | Telomere Shortening | Adenine - adverse effects | HIV Infections - pathology | Time Factors | Polymerase Chain Reaction | Adult | Deoxycytidine - adverse effects | Female | Telomerase - metabolism | Dideoxynucleosides - adverse effects | Emtricitabine | Adenine - analogs & derivatives | Leukocytes, Mononuclear - drug effects | Zidovudine - adverse effects | Anti-HIV Agents - adverse effects | HIV Infections - virology | Risk Factors | Cells, Cultured | Organophosphonates - adverse effects | HIV - pathogenicity | Enzyme Activation - drug effects | Regression Analysis | Telomere - enzymology | HIV Infections - drug therapy | Leukocytes, Mononuclear - enzymology | Telomerase - antagonists & inhibitors | Deoxycytidine - analogs & derivatives | Complications and side effects | Demographic aspects | Physiological aspects | Aging | Research | Telomerase
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 10/2010, Volume 51, Issue 8, pp. 963 - 972
Journal Article
AIDS (London, England), ISSN 0269-9370, 2013, Volume 27, Issue 5, pp. 803 - 813
To estimate the incidence of and risk factors for modifications to first antiretroviral therapy (ART) regimen, treatment interruption and death. A total of 21... 
HIV/AIDS | MORTALITY | FRENCH-HOSPITAL-DATABASE | INFECTIOUS DISEASES | competing-risk method | VIROLOGICAL TREATMENT FAILURE | survival | AIDS | COMPETING RISKS | IMMUNOLOGY | DISCONTINUATION | switch | antiretroviral | VIROLOGY | RECOMMENDATIONS | ACTIVE ANTIRETROVIRAL THERAPY | interruption | INFECTED PATIENTS | COHORT | HIV-1 | United States - epidemiology | Lamivudine - administration & dosage | Humans | HIV Seropositivity - mortality | HIV Seropositivity - drug therapy | Nevirapine - adverse effects | Reverse Transcriptase Inhibitors - administration & dosage | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Reverse Transcriptase Inhibitors - adverse effects | Tenofovir | Adenine - adverse effects | Time Factors | Deoxycytidine - adverse effects | HIV Infections - mortality | Dideoxynucleosides - adverse effects | Antiretroviral Therapy, Highly Active - methods | Dideoxynucleosides - administration & dosage | Emtricitabine | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Risk Factors | Organophosphonates - adverse effects | Europe - epidemiology | Benzoxazines - adverse effects | HIV Protease Inhibitors - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Lopinavir - administration & dosage | HIV Infections - drug therapy | Nevirapine - administration & dosage | Deoxycytidine - analogs & derivatives | Drug Combinations | Lopinavir - adverse effects | Cohort Studies
Journal Article
Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 09/2010, Volume 55, Issue 1, pp. 49 - 57
Background: Abacavir/lamivudine and tenofovir/emtricitabine fixed-dose combinations are commonly used first-line antiretroviral therapies, yet few studies have... 
HIV-1 | Efficacy | Abacavir/lamivudine | Tenofovir/emtricitabine | Cardiovascular | Renal | ABACAVIR | tenofovir/emtricitabine | INFECTIOUS DISEASES | MYOCARDIAL-INFARCTION | CARDIOVASCULAR EVENTS | THYMIDINE ANALOG | TENOFOVIR DF | RISK | IMMUNOLOGY | cardiovascular | efficacy | abacavir/lamivudine | HIV-INFECTED PATIENTS | renal | REVERSE-TRANSCRIPTASE INHIBITORS | THERAPY | CHRONIC KIDNEY-DISEASE | Lamivudine - administration & dosage | Humans | Middle Aged | Male | Viral Load | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Tenofovir | Young Adult | Glomerular Filtration Rate - drug effects | Adenine - adverse effects | HIV-1 - isolation & purification | Adult | Deoxycytidine - adverse effects | Female | Dideoxynucleosides - adverse effects | Dideoxynucleosides - administration & dosage | Emtricitabine | Adenine - analogs & derivatives | Kidney - drug effects | Benzoxazines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | beta 2-Microglobulin - urine | Benzoxazines - adverse effects | Treatment Outcome | Retinol-Binding Proteins - urine | Adenine - administration & dosage | Organophosphonates - administration & dosage | Adolescent | HIV Infections - drug therapy | Aged | Deoxycytidine - analogs & derivatives | Drug Combinations
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 11/2013, Volume 369, Issue 19, pp. 1807 - 1818
Journal Article
JAIDS Journal of Acquired Immune Deficiency Syndromes, ISSN 1525-4135, 05/2007, Volume 45, Issue 1, pp. 34 - 42
BACKGROUND:The effects of HIV infection, highly active antiretroviral therapy (HAART), and specific antiretroviral agents on lipoproteins in women are not well... 
Low-density lipoprotein | Women | Highly active antiretroviral therapy | Lipids | High-density lipoprotein | INFECTIOUS DISEASES | lipids | high-density lipoprotein | BODY-COMPOSITION | IMMUNOLOGY | INSULIN SENSITIVITY | PROTEASE INHIBITORS | low-density lipoprotein | DIABETES-MELLITUS | NAIVE SUBJECTS | DENSITY-LIPOPROTEIN CHOLESTEROL | THERAPY | PLASMA-CONCENTRATIONS | highly active antiretroviral therapy | INFECTED PATIENTS | LOPINAVIR/RITONAVIR | women | Cholesterol - blood | Didanosine - adverse effects | Humans | Antiretroviral Therapy, Highly Active - adverse effects | Hispanic Americans - statistics & numerical data | Nevirapine - adverse effects | Tenofovir | Adenine - therapeutic use | Stavudine - therapeutic use | Lamivudine - therapeutic use | Ritonavir - therapeutic use | Dideoxynucleosides - adverse effects | HIV Protease Inhibitors - adverse effects | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Organophosphonates - adverse effects | HIV Protease Inhibitors - therapeutic use | HIV-1 | Didanosine - therapeutic use | Multivariate Analysis | Lipoproteins, HDL - blood | United States | HIV Seropositivity - drug therapy | Nevirapine - therapeutic use | Lamivudine - adverse effects | Adenine - adverse effects | Ritonavir - adverse effects | Stavudine - adverse effects | Lipids - blood | Adult | Anti-HIV Agents - therapeutic use | Female | Dideoxynucleosides - therapeutic use | Drug Therapy, Combination | HIV Seronegativity | Nelfinavir - therapeutic use | Fasting | Cross-Sectional Studies | Anti-HIV Agents - adverse effects | Benzoxazines - adverse effects | European Continental Ancestry Group - statistics & numerical data | Benzoxazines - therapeutic use | Nelfinavir - adverse effects | African Continental Ancestry Group - statistics & numerical data | Triglycerides - blood | HIV Infections - drug therapy | Indinavir - adverse effects | Lipoproteins, LDL - blood | HIV Infections - metabolism | Indinavir - therapeutic use | Measurement | Complications and side effects | Dosage and administration | Blood lipids | Health aspects | HIV infection
Journal Article
Nature, ISSN 0028-0836, 09/2016, Volume 537, Issue 7619, pp. S60 - S62
Drug-Related Side Effects and Adverse Reactions - prevention & control | Humans | Warfarin - metabolism | Warfarin - adverse effects | Male | Antidepressive Agents - metabolism | Warfarin - administration & dosage | Warfarin - therapeutic use | Evidence-Based Medicine - trends | Precursor Cell Lymphoblastic Leukemia-Lymphoma - drug therapy | Pharmacogenetics - trends | Purine-Pyrimidine Metabolism, Inborn Errors - complications | Mercaptopurine - therapeutic use | Drug Hypersensitivity - enzymology | Drug-Related Side Effects and Adverse Reactions - genetics | Drug Hypersensitivity - genetics | Mercaptopurine - metabolism | Succinylcholine - adverse effects | Dideoxynucleosides - adverse effects | Drug Hypersensitivity - complications | Child | HLA-B Antigens - genetics | Precursor Cell Lymphoblastic Leukemia-Lymphoma - complications | Pharmacogenetics - methods | HIV Infections - genetics | Mercaptopurine - administration & dosage | Mercaptopurine - adverse effects | Purine-Pyrimidine Metabolism, Inborn Errors - enzymology | Antidepressive Agents - therapeutic use | Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics | Genetic Testing - utilization | Purine-Pyrimidine Metabolism, Inborn Errors - genetics | Precision Medicine - trends | Precursor Cell Lymphoblastic Leukemia-Lymphoma - enzymology | Antidepressive Agents - administration & dosage | HIV Infections - drug therapy | Antidepressive Agents - adverse effects | Primaquine - adverse effects | Precision Medicine - methods
Journal Article
Journal of Human Genetics, ISSN 1434-5161, 06/2013, Volume 58, Issue 6, pp. 317 - 326
Rare but severe adverse drug reactions (ADRs) are an important issue in drug development and in the proper usage of drugs during the post-approval phase. The... 
drug-induced liver injury | pharmacogenomics | severe cutaneous adverse reactions | human leukocyte antigen | genome-wide association study | HLA CLASS-I | TOXIC EPIDERMAL NECROLYSIS | CLASS-II GENOTYPE | GENETIC SUSCEPTIBILITY | RISK-FACTOR | GENETICS & HEREDITY | GENOME-WIDE | HLA-B-ASTERISK-1502 ALLELE | JAPANESE PATIENTS | STEVENS-JOHNSON-SYNDROME | ABACAVIR HYPERSENSITIVITY | HLA-DQ alpha-Chains - immunology | Stevens-Johnson Syndrome - immunology | Benzylamines - adverse effects | Humans | HLA Antigens - genetics | HLA-DQ alpha-Chains - genetics | Drug Hypersensitivity - genetics | Ticlopidine - adverse effects | Amoxicillin-Potassium Clavulanate Combination - adverse effects | Dideoxynucleosides - adverse effects | HLA-B Antigens - genetics | Skin - pathology | Skin - immunology | Pharmacogenetics | Diclofenac - analogs & derivatives | Diclofenac - adverse effects | Azetidines - adverse effects | HLA-B Antigens - immunology | HLA Antigens - immunology | Chemical and Drug Induced Liver Injury - genetics | Floxacillin - adverse effects | Genetic Markers | Chemical and Drug Induced Liver Injury - immunology | Drug Hypersensitivity - pathology | HLA-A Antigens - immunology | Stevens-Johnson Syndrome - genetics | Carbamazepine - adverse effects | Drug Hypersensitivity - immunology | Alleles | Allopurinol - adverse effects | HLA-A Antigens - genetics | Quinazolines - adverse effects | Skin - drug effects | Index Medicus
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 11/2009, Volume 49, Issue 10, pp. 1591 - 1601
Background. There are 2 once-daily, fixed-dose-combination, dual–nucleoside analogue tablets: tenofovir 300 mg–emtricitabine 200 mg (TDF-FTC) and abacavir 600... 
Myocardial infarction | HIV/AIDS | Antiretrovirals | HIV | Protease inhibitors | HDL lipoproteins | AIDS | Experimentation | Bone density | Cholesterols | Virology | INFECTIOUS DISEASES | REVERSE-TRANSCRIPTASE INHIBITORS | MYOCARDIAL-INFARCTION | RISK | MICROBIOLOGY | IMMUNOLOGY | HIV-INFECTED PATIENTS | Lamivudine - administration & dosage | Humans | Middle Aged | Male | Dideoxynucleosides | Viral Load | Anti-HIV Agents - administration & dosage | Lamivudine - adverse effects | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Drug-Related Side Effects and Adverse Reactions | Lamivudine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | HIV Infections - mortality | Antiretroviral Therapy, Highly Active - methods | HLA-B Antigens - genetics | Emtricitabine | Adenine - analogs & derivatives | Organophosphonates - therapeutic use | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Treatment Outcome | Adenine - administration & dosage | Organophosphonates - administration & dosage | HIV Infections - complications | HIV Infections - drug therapy | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | Usage | Drug therapy, Combination | HIV (Viruses) | Drug therapy | Health aspects
Journal Article